Intel Corporation (INL)
XETRA Stock Exchange · Germany · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 77.79 |
|---|---|
| 52-week range | 28.51 – 123.80 |
| Return, 1 month / 3 months | −26.8% / −12.5% |
| Return, 1 year / 3 years | +141.8% / +141.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 33 |
| Volatility (1 year) | 73.9% |
| Worst drawdown (1 year) | -40.4% |
| Average daily value traded | 4.51M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Intel Corporation designs and manufactures semiconductors, chiefly the processors that power personal computers and servers. The company makes central processing units, chipsets and related silicon, along with networking and memory products, serving computer manufacturers, data centre operators and device makers. Intel also supplies software and platform technologies that support its hardware. The company is based in Santa Clara, California, in the United States, and sells its products to customers in markets around the world.
On this site Intel Corporation appears as a stock on the XETRA Stock Exchange (Germany), code INL, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Intel Corporation (INL) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 77.79 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 303 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 141.8% and over the last three months it fell 12.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 61 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.1% | ||
| From 52-week high | -36.7% | ||
| Momentum | 72 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -12.5% | ||
| 6-month return | 34.8% | ||
| 12-month return, skipping the last month | 230.5% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 73.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.4% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 4.51M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.6% |
|---|---|
| 1 month | −26.8% |
| 3 months | −12.5% |
| 6 months | +34.8% |
| 1 year | +141.8% |
| 3 years | +141.7% |
| 5 years | +95.8% |
Signals
| 50-day / 200-day average | 89.43 / 75.44 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.77 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Aug 2024 | USD 0.1112 |
| 6 May 2024 | USD 0.1112 |
| 6 Feb 2024 | USD 0.1112 |
| 6 Nov 2023 | USD 0.1112 |
| 4 Aug 2023 | USD 0.1112 |
| 4 May 2023 | USD 0.1112 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.